Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

69.96USD
18 Aug 2017
Change (% chg)

$0.11 (+0.16%)
Prev Close
$69.85
Open
$69.52
Day's High
$70.44
Day's Low
$69.47
Volume
4,015,967
Avg. Vol
5,413,833
52-wk High
$75.04
52-wk Low
$55.06

Latest Key Developments (Source: Significant Developments)

Abbvie initiates phase 2 clinical trial programs for ABBV-8e12
Wednesday, 25 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie initiates phase 2 clinical trial programs for ABBV-8e12, an investigational anti-tau antibody, in early alzheimer's disease and progressive supranuclear palsy.  Full Article

AbbVie, Genomics Medicine and WuXi NextCODE announce Population Genomics alliance
Monday, 9 Jan 2017 08:05am EST 

AbbVie Inc :Abbvie - Co, Genomics Medicine Ireland, WuXi NextCODE announce Population Genomics alliance; financial terms were not disclosed.  Full Article

Abbvie announces four new collaborations and investments with healthcare companies
Monday, 9 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie Inc - announced four new collaborations and investments with healthcare companies.  Full Article

AbbVie, Lurie Cancer Center to collaborate on multi-year cancer research agreement
Monday, 5 Dec 2016 08:50am EST 

AbbVie Inc :AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement.  Full Article

Halozyme provides update on Abbvie collaboration
Monday, 21 Nov 2016 08:30am EST 

Halozyme Therapeutics Inc : Halozyme Therapeutics Inc - abbvie has discontinued a development program using halozyme enhanze platform technology . Halozyme - co, abbvie will continue to work to identify additional targets for co-development under 2015 global collaboration,licensing agreement . Halozyme Therapeutics - abbvie has discontinued development program following completion of a phase 1 study in which target results were not achieved . Halozyme Therapeutics-abbvie discontinued development program using halozyme enhanze platform technology, tnf-alpha target after completion of phase 1 study .Halozyme provides update on abbvie collaboration.  Full Article

Abbvie's Humira® (adalimumab) receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa
Monday, 14 Nov 2016 03:00am EST 

Abbvie Inc : Abbvie's Humira receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa, a chronic inflammatory skin disease .Says "if approved, Humira will become first and only biologic treatment option for patients 12 years of age and older".  Full Article

CHMP recommends EU approval of Venclyxto in hard-to-treat CLL-Roche
Friday, 14 Oct 2016 07:16am EDT 

Roche Holding AG :Says : roche announces CHMP recommendation for eu approval of venclyxto for people with hard-to-treat chronic lymphocytic leukaemia.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 07:00am EDT 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

U.S. FDA approves Amjevita, a biosimilar to Humira
Friday, 23 Sep 2016 04:47pm EDT 

U.S. FDA : Fda approves Amjevita, a biosimilar to Humira .Approved Amjevita (Adalimumab-Atto) as a biosimilar to Humira (Adalimumab) for multiple inflammatory diseases.  Full Article

arGEN X cash position at June end doubles to 108.7 mln euros
Friday, 26 Aug 2016 01:00am EDT 

arGEN X BV : Q2 revenue is 5.7 million euros ($6.4 million) versus 2.7 million euros year ago . Q2 total operating income is 7.0 million euros versus 4.3 million euros a year ago . Q2 net loss is 7.4 million euros versus loss of 7.0 million euros a year ago . At June 30 cash position of 108.7 million euros (cash, cash-equivalents and financial assets) versus 50.5 million euros a year ago . Phase 2 study in first auto-immune indication planned to start by year-end . Cash position strengthened by $40 million upfront payment from AbbVie and 30 million euros private placement .On ARGX-110 t-cell lymphoma (TCL) - top line date to be presented by end 2016, first combination study to start in H2 2016.  Full Article

BRIEF-Abbvie's Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes

* Abbvie's Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes Source text for Eikon: Further company coverage: